How CREBBP and KMT2D gene changes help B‑cell lymphoma avoid the immune system
Project 1 Melnick
Testing whether common CREBBP and KMT2D gene changes let B‑cell lymphomas hide from the immune system in people with B‑cell lymphoma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11167634 on NIH RePORTER |
What this research studies
If you have B‑cell lymphoma, this project looks at how two common gene changes (CREBBP and KMT2D) change the way tumor cells control immune signals. Researchers will study patient tumor samples and laboratory models, including 3‑D approaches, to watch how gene regulation and enhancer activity are altered. They will examine how those changes affect interactions between lymphoma cells and immune cells in the tumor microenvironment. Findings could point to ways to restore immune recognition of these lymphomas or guide targeted therapies.
Who could benefit from this research
Good fit: People with B‑cell lymphoma—especially those whose tumors carry CREBBP or KMT2D mutations or that arise from germinal‑center B cells—would be most directly relevant.
Not a fit: People with non‑B‑cell cancers or lymphomas that do not have these specific epigenetic mutations are less likely to benefit directly from this project.
Why it matters
Potential benefit: Could identify ways to restore immune recognition of B‑cell lymphomas and suggest new targeted or immune‑based treatments.
How similar studies have performed: Prior work has shown CREBBP and KMT2D mutations disrupt gene enhancers and immune signaling, but studying how they cooperate and reshape the immune microenvironment is a newer direction being tested here.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Melnick, Ari M. — Weill Medical Coll of Cornell Univ
- Study coordinator: Melnick, Ari M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.